Targeted ADC Expansion Leverage Tagworks’ Click-to-Release platform and TGW101 targeting TAG72 to pursue partnerships with oncology clinics and biopharma seeking novel solid tumor therapies, emphasizing collaboration on ADCs and other Click-to-Release modalities.

Clinical Collaboration Growth Capitalize on recent IND clearance and Phase 1 initiation to engage translational and clinical research organizations, academic centers, and investigator-initiated trials for TGW101 and TGW211 to accelerate study enrollment and data generation.

Strategic Partnerships Position Tagworks as a partner for university medical centers and radiopharmacy networks (notably Radboudumc and imaging-focused sites) to expand first-in-human studies and imaging trials in HER2-positive and other solid tumor cohorts.

Global Access Potential Highlight Netherlands headquarters with U.S. operations to appeal to global pharma players seeking cross-border development and manufacturing capabilities, offering distributed clinical trial support and potential regional manufacturing options.

Clinical and Tech Integration Offer integrated collaboration packages combining ADC and targeted radiopharmaceutical capabilities, backed by existing tech stack and data tools, enabling partners to align regulatory, imaging, and biomarker strategies for faster go/no-go decisions.